About Opaxio™

Opaxio™ (Oh-PACKS-ee-oh) (paclitaxel poliglumex) is an investigational, biologically enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, resulting in a new chemical entity. When bound to the polymer, paclitaxel is inactive, potentially sparing normal tissue's exposure to high levels of paclitaxel and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to macromolecules such as Opaxio. Based on preclinical studies, it appears that Opaxio is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed, allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing active paclitaxel. Unlike standard radiosensitizing agents, Opaxio appears tumor selective and does not appear to enhance radiation toxicity to normal tissues.

Development Status


Opaxio in Action


Opaxio in Action

Opaxio is our biologically enhanced chemotherapeutic that links paclitaxel to a biodegradable polymer using our polyglutamate drug delivery technology. Opaxio was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects.


You are now leaving website and entering the website.

If you would like to continue, click Continue.